Abstracts

CHARACTERIZATION OF THE DOLUTEGRAVIR MONOTHERAPY-ACQUIRED S230R RESISTANCE MUTATION

Dolutegravir (DTG) is a potent and well tolerated integrase strand-transfer inhibitor (INSTI) with a high barrier to resistance, which makes it a suitable candidate for antiretroviral maintenance monotherapy and simplified regimens. Here, we report the emergence of a S230R substitution in two patients who experienced virological failure after switching to DTG monotherapy from triple therapy…

IN VITRO SELECTED RESISTANCE TO NEW INTEGRASE INHIBITORS BY B & NON-B SUBTYPE VIRUSES

The integrase strand transfer inhibitors (INSTIs) bictegravir (BIC), dolutegravir (DTG), and cabotegravir (CAB) have improved resistance profiles when compared to raltegravir and elvitegravir (EVG), with few reported cases of resistance in the clinic. This study used in vitro drug selections with primary HIV-1 isolates to examine potential pathways for resistance to EVG and DTG and…

UTILITY OF POC XPERT HIV-1 TESTS FOR DETECTION-QUANTIFICATION OF COMPLEX RECOMBINANTS

Implementation of simple point-of-care (POC) molecular assays for early infant HIV diagnosis (EID) and viral load (VL) quantification for early treatment failure identification can improve HIV monitoring in settings with limited laboratory infrastructure. However, they should be evaluated in areas with extremely high diversity of HIV-1 variants. We analyzed the efficacy of two POC techniques…

RELATIVE SENSITIVITIES OF 4TH AND 5TH GEN COMBO HIV AG/AB, P24 AND VIRAL LOAD ASSAYS

Detection of acute HIV infection is critical to HIV public health and diagnostics. HIV Ag/Ab combo (4th/5th gen) immunoassays have reduced the HIV diagnostic window period by enhancing detection of acute infection, but require ongoing evaluation with currently circulating diverse subtypes. Genetically and geographically diverse, well-characterized HIV clinical isolates assembled by the NIAID Supported EQAPOL…

INCREASING POSITIVITY FOR NON-PLASMA SAMPLES USING THE ABBOTT REALTIME HIV-1 ASSAY

Measuring HIV-1 RNA levels in various biological compartments of infected patients provides insight to viral shedding, transmission, reservoirs, and pathological manifestations. Commercial HIV-1 RNA quantitative assays approved by the FDA for plasma samples are often used to quantify HIV-1 RNA in non-plasma specimens. Endocervical swabs, for example, contain bacterial and human byproducts which may affect…

EVALUATION OF THE CDC/APHL HIV DIAGNOSTIC ALGORITHM WITH RECENTLY FDA-APPROVED ASSAYS

Two serologic assays, the BioPlex 2200 HIV Ag-Ab screening assay (BPC) that detects and differentiates p24 antigen (Ag) and HIV-1 and HIV-2 antibodies (Ab) and the GeeniusTM HIV-1/2 supplemental assay (Geenius) that differentiates HIV-1 from HIV-2 Ab, were approved after the 2014 CDC/APHL laboratory HIV diagnostic algorithm was released. We evaluated the performance of these…